 |
TREATMENTS IN THE PIPELINE: 150 headlines |
|
|||||
My Educational Video on MS and MS Trials| Visitors Since 03/2006 |
||||||||||||||||||||||||||||||||||||||
| Our 670 MySpace Friends The New Face of MS |
||||||||||||||||||||||||||||||||||||||
 |
||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
 Click to view 1280 MS Walk photos! | ||||||||||||||||||||||||||||||||||||||
| "Join a trial at Barrow & receive all medication & study based procedures at no charge!" | ||||||||||||||||||||||||||||||||||||||
Stan Swartz, CEO, The MD Health Channel "WE PRODUCED THE FOLLOWING 9 VIDEOS FOR YOU!" Simply click the "video" buttons below: . |
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Previious Posts | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| MS NEWS ARCHIVES: by week | ||||||||||||||||||||||||||||||||||||||
| June 2006 | ||||||||||||||||||||||||||||||||||||||
| July 2006 | ||||||||||||||||||||||||||||||||||||||
| August 2006 | ||||||||||||||||||||||||||||||||||||||
| September 2006 | ||||||||||||||||||||||||||||||||||||||
| October 2006 | ||||||||||||||||||||||||||||||||||||||
| November 2006 | ||||||||||||||||||||||||||||||||||||||
Monday
Pfizer's Lyrica(R) (Pregabalin Capsules) Approved in Europe for Difficult-to-Treat Nerve Pain....CLICK FOR FULL ARTICLE
Lyrica's neuropathic pain indication broadened to include central nerve pain; Central nerve pain is associated with conditions such as spinal cord injury, stroke, and multiple sclerosis
A robust and unprecedented clinical program involving more than 10,000 patients supports Lyrica's efficacy and safety in treating a broad range of neurological disorders
Medical Expert: 'Physicians will be in a better position to manage a whole host of difficult-to-treat nerve pains for many of their patients.'
NEW YORK, NY -- September 19, 2006 -- Pfizer Inc said today that the European Commission approved Lyrica(R) (pregabalin capsules) to treat central neuropathic (nerve) pain.
This new approval broadens the current range of neuropathic pain that Lyrica is approved to treat in Europe to include nerve pain associated with conditions such as spinal cord injury, stroke, and multiple sclerosis.
Central neuropathic pain can be an especially difficult-to-treat condition, often requiring the use of strong narcotics. Lyrica's approval in central neuropathic pain provides further evidence of its robust efficacy in even the most hard to treat neuropathic pain conditions. Now, Lyrica is the only medication approved in the EU to treat both peripheral and central neuropathic pain, which affects up to 7.7 million people in Europe.
Developed by Pfizer, Lyrica is believed to work by calming hyper-excited neurons which may be an underlying cause for various types of nerve pain......more
Lyrica's neuropathic pain indication broadened to include central nerve pain; Central nerve pain is associated with conditions such as spinal cord injury, stroke, and multiple sclerosis
A robust and unprecedented clinical program involving more than 10,000 patients supports Lyrica's efficacy and safety in treating a broad range of neurological disorders
Medical Expert: 'Physicians will be in a better position to manage a whole host of difficult-to-treat nerve pains for many of their patients.'
NEW YORK, NY -- September 19, 2006 -- Pfizer Inc said today that the European Commission approved Lyrica(R) (pregabalin capsules) to treat central neuropathic (nerve) pain.
This new approval broadens the current range of neuropathic pain that Lyrica is approved to treat in Europe to include nerve pain associated with conditions such as spinal cord injury, stroke, and multiple sclerosis.
Central neuropathic pain can be an especially difficult-to-treat condition, often requiring the use of strong narcotics. Lyrica's approval in central neuropathic pain provides further evidence of its robust efficacy in even the most hard to treat neuropathic pain conditions. Now, Lyrica is the only medication approved in the EU to treat both peripheral and central neuropathic pain, which affects up to 7.7 million people in Europe.
Developed by Pfizer, Lyrica is believed to work by calming hyper-excited neurons which may be an underlying cause for various types of nerve pain......more